| A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. | None |
| mTORC1 pathway and the oncogenic Ras/Raf/MEK/extracellular signal-regulated kinase (ERK) pathway cooperate to restrict eEF2K activity. | None |
| A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. | None |
| Carcinogenic ability of possibly through oncogenic mutation of gene. | None |
| IER3 supports KRASG12D-associated oncogenesis in the pancreas by sustaining ERK1/2 phosphorylation via phosphatase PP2A inhibition. | None |
| Molecular cloning of the 25 kbp region upstream of exon 0 of the human Ki-ras oncogene and its conservation in transformed mouse NIH 3T3 cells. | None |
| Oncogenic Ras stimulates Eiger/TNF exocytosis to promote growth. | None |
| Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. | None |
| Oncogenic STRAP functions as a novel negative regulator of E-cadherin and p21(Cip1) by modulating the transcription factor Sp1. | None |
| Transcriptional activation of cKi-ras proto-oncogene resulting from retroviral promoter insertion. | None |
| p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?. | None |
| Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. | None |
| Expression of ras oncogene p21 during human fetal development as determined by monoclonal antibodies RAP-5, Y13-259, and DWP. | None |
| oncogenic K-Ras is able to induce significant alterations in mitochondrial protein expression, and identified NDUFAF1 as an important molecule whose low expression contributes to mitochondrial dysfunction induced by K-Ras. | None |
| The Akt1(Myr)/KRas(G12D) model holds promise for delineating the tumor biology and biomarkers critical for understanding their cooperation in cancer oncogenesis and future targeting in therapeutic strategies. | None |
| Expression of ki-ras oncogene in tumor cell variants exhibiting different metastatic capabilities. | None |
| Casein kinase 1alpha is a key negative regulator of oncogenic RAS-induced autophagy. Depletion or pharmacologic inhibition of CK1alpha enhanced autophagic flux in oncogenic RAS-driven human fibroblasts and multiple cancer cell lines. | None |
| Our results suggest that DNMT3A mutations and oncogenic RAS cooperate to regulate hematopoietic stem and progenitor cells and promote myeloid malignancies. | None |
| miR-155 plays an important role in oncogenic K-Ras transformation mediated by cellular redox regulation | None |
| Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. | None |